WKN:874950
sehr Interessanter Biowert!
sehr Interessanter Biowert!
Anzeige
Meldung des Tages: 1.000% Prognose: Diese Aktie kann 2026 voll durchstarten!
Bioject Medical Technologies!!!
Beiträge:
28
Zugriffe: 8.348 / Heute: 1
Zugriffe: 8.348 / Heute: 1
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI Korea UCITS ETF 1C
Perf. 12M: +61,04%
Xtrackers Spain UCITS ETF 1D
Perf. 12M: +59,11%
Xtrackers Spain UCITS ETF 1C
Perf. 12M: +58,89%
Xtrackers ATX UCITS ETF 1C
Perf. 12M: +51,46%
Xtrackers Vietnam Swap UCITS ETF 1C
Perf. 12M: +49,01%
&a=874950&b=0&banner_ref=HASH(0x9886fc4)&zeitraum=8&ind_volume=ON&zoom.x=0&zeitbis=&bis=1106953539.88669&bname=&cookies=HASH(0x9ee43cc)&req_host=ARRAY(0xa08bb40)&zeitvon=0&von=0)
Was soll an diesem Wert interessant sein ?
Da er bei 1 Euro ist, das der Chart nach weiter fallenden Kursen schreit, das die Firma vielleicht schon bald über den Deister geht ?
Handel wohl nur am Nebenbörsenplatz Bremen/Berlin !
Marktenger Wwert, der sich durch Meinungsmache schnell beeinflussen läßt, nix für mich !
Wo bleiben die überzeugenden Fakten.
Das soll doch wohl keinen Push darstellen, oder ?
Gruß Byblos
Da er bei 1 Euro ist, das der Chart nach weiter fallenden Kursen schreit, das die Firma vielleicht schon bald über den Deister geht ?
Handel wohl nur am Nebenbörsenplatz Bremen/Berlin !
Marktenger Wwert, der sich durch Meinungsmache schnell beeinflussen läßt, nix für mich !
Wo bleiben die überzeugenden Fakten.
Das soll doch wohl keinen Push darstellen, oder ?
Gruß Byblos
das ich ein US Wert pushen kann! Desweiteren ist der Wert interessant, da enge Marktkapitalisierung für Nasdaqbörse! Zudem Biotrend nicht zu vergessen.
16.12.2004 14:37:
Bioject Receives Milestone Payment From Merial
BEDMINSTER, N.J., Dec. 16 /PRNewswire-FirstCall/ -- Bioject Medical Technologies (Nachrichten) today announced that during the fourth quarter it has received a milestone payment from Merial, a world-leading animal health company. The milestone payment is part of a collaboration agreement established in March 2004 for Merial's use of a modified version of Bioject's Vitajet(R) needle-free delivery system for the companion animal market (cats and dogs). The payment is based upon the regulatory approval of a vaccine that was developed by Merial and will be administered utilizing Bioject's needle-free system. In addition, during the quarter, Bioject earned a second milestone payment based upon the delivery of ten prototype devices to Merial.
Jim O'Shea, Chairman and CEO of Bioject commented, "We continue to be very pleased with our Merial collaborations and our joint achievement of receiving regulatory approval in less than nine months. We are looking forward to the commercial launch of the product for the companion animal market during the first quarter of 2005."
Bioject Medical Technologies Inc., based in Bedminster, New Jersey, and Portland, Oregon, is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The Company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Bioject's expectations with respect to payments under its agreement with Merial and the timing of the commercial launch of the Vitajet needle free delivery system in the companion animal market. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties and other factors include, without limitation, the risk that Bioject will be unable to maintain its existing relationship with Merial, the risk that the Company will be unable to obtain needed debt or equity financing to finance its product development efforts on satisfactory terms, or at all, uncertainties related to Bioject's dependence on the continued performance of strategic partners such as Merial, uncertainties related to the time required for the Company or its strategic partners such as Merial to complete research and development and obtain necessary clinical data and government clearances, the risk that the Company may be unable to produce its products at a unit cost necessary for the products to be competitive in the market and the risk that the Company may be unable to comply with the extensive government regulations applicable to Bioject's business. Readers of this press release are referred to the Company's filings with the Securities and Exchange Commission, including the Company's reports on Form 10-K and Forms 10-Q for further discussions of factors that could affect the Company's business and its future results. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. The Company assumes no obligation to update forward-looking statements if conditions or management's estimates or opinions should change.
For more information on Bioject, visit www.bioject.com/.
Bioject Medical Technologies Inc.
16.12.2004 14:37:
Bioject Receives Milestone Payment From Merial
BEDMINSTER, N.J., Dec. 16 /PRNewswire-FirstCall/ -- Bioject Medical Technologies (Nachrichten) today announced that during the fourth quarter it has received a milestone payment from Merial, a world-leading animal health company. The milestone payment is part of a collaboration agreement established in March 2004 for Merial's use of a modified version of Bioject's Vitajet(R) needle-free delivery system for the companion animal market (cats and dogs). The payment is based upon the regulatory approval of a vaccine that was developed by Merial and will be administered utilizing Bioject's needle-free system. In addition, during the quarter, Bioject earned a second milestone payment based upon the delivery of ten prototype devices to Merial.
Jim O'Shea, Chairman and CEO of Bioject commented, "We continue to be very pleased with our Merial collaborations and our joint achievement of receiving regulatory approval in less than nine months. We are looking forward to the commercial launch of the product for the companion animal market during the first quarter of 2005."
Bioject Medical Technologies Inc., based in Bedminster, New Jersey, and Portland, Oregon, is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The Company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Bioject's expectations with respect to payments under its agreement with Merial and the timing of the commercial launch of the Vitajet needle free delivery system in the companion animal market. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties and other factors include, without limitation, the risk that Bioject will be unable to maintain its existing relationship with Merial, the risk that the Company will be unable to obtain needed debt or equity financing to finance its product development efforts on satisfactory terms, or at all, uncertainties related to Bioject's dependence on the continued performance of strategic partners such as Merial, uncertainties related to the time required for the Company or its strategic partners such as Merial to complete research and development and obtain necessary clinical data and government clearances, the risk that the Company may be unable to produce its products at a unit cost necessary for the products to be competitive in the market and the risk that the Company may be unable to comply with the extensive government regulations applicable to Bioject's business. Readers of this press release are referred to the Company's filings with the Securities and Exchange Commission, including the Company's reports on Form 10-K and Forms 10-Q for further discussions of factors that could affect the Company's business and its future results. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. The Company assumes no obligation to update forward-looking statements if conditions or management's estimates or opinions should change.
For more information on Bioject, visit www.bioject.com/.
Bioject Medical Technologies Inc.
ich habe die Aktie in meine Watchliste aufgenommen und hoffe, daß Teil geht noch unter 1 USD! Damals in der Boomzeit hatte ich schon mal Glück mit diesen Wert, ging bis etwa 0,25 USD runter und dann ...
Kaufen nur an der Heimatbörse!
Kaufen nur an der Heimatbörse!
Initial Study Shows Needle-free Administration of FUZEON® Achieves Equivalent Drug Levels Compared To Standard Needle Administration
NUTLEY, N.J. and MORRISVILLE, N.C. – January 27, 2005 – Data recently presented at HIV DART - Frontiers in Drug Development for Antiretroviral Therapies show that patients who were administered a single FUZEON® (enfuvirtide) dose with a needle-free injection device (Biojector® 2000) achieved equivalent drug levels in the blood compared to those who were administered FUZEON with the standard needle (27G ½") and syringe.
This study was a controlled, randomized open-label crossover pharmacokinetic evaluation of HIV-infected patients with viral loads below 1000 copies/mL. The study enrolled 27 patients who received FUZEON for the first time. A study nurse administered single abdominal subcutaneous doses of FUZEON (90mg) with either the Biojector needle-free injection device or a standard 27G ½" needle and syringe. This was followed by a second dose of equal strength administered using the alternate device by the same study nurse, seven days later. The drug levels in the blood were measured over 48 hours and each of the standard comparisons (maximum concentration, minimum concentration, and overall exposure) demonstrated bioequivalence.
The Biojector 2000 injection system, manufactured by Bioject Medical Technologies Inc., is a needle-free CO2-powered injector that disperses fluid through the skin. Biojector 2000 received approval in 1996 to deliver subcutaneous and intramuscular injections and has been used in vaccine delivery, chronic therapy and other settings, delivering millions of injections worldwide (for more information: www.bioject.com or 800.683.7221).
Based on the data from this study, Roche and Trimeris are exploring plans to further evaluate use of FUZEON with this needle-free injection system.
Facts About Fuzeon
FUZEON is the first and only fusion inhibitor for the treatment of HIV. Unlike other HIV drugs that work after HIV has entered the human immune cell, FUZEON works outside the CD4 cell, blocking HIV from entering the cell. For this reason, FUZEON is effective in treatment-experienced patients who have developed resistance to other anti-HIV drugs, though patients may still develop resistance to FUZEON. FUZEON was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in March 2003 on the basis of 24-week data, and was granted traditional (full) approval on Oct. 15, 2004 on the basis of long-term 48-week data.
Injection Site Reactions (ISRs): ISRs are the most common adverse events associated with FUZEON. ISRs occurred in 98% of patients studied and 4% discontinued FUZEON due to ISRs. Signs/symptoms may include pain and discomfort, hardened skin, redness, bumps, itching and swelling. Eleven percent of patients had local reactions that required analgesics or limited usual activities.
Pneumonia: An increased rate of bacterial pneumonia was observed in subjects treated with FUZEON in the Phase III clinical trials compared to the control arm. It is unclear if the increased incidence of pneumonia is related to FUZEON use. Patients with HIV infection should be carefully monitored for signs and symptoms of pneumonia. Risk factors for pneumonia included low initial CD4 cell count, high initial viral load, intravenous drug use, smoking and a prior history of lung disease.
Hypersensitivity Reactions: Systemic hypersensitivity reactions have been associated with FUZEON therapy and may recur on rechallenge. Hypersensitivity reactions have included individually and in combination: rash, fever, nausea and vomiting, chills, rigors, hypotension and elevated serum liver transaminases. Other adverse events that may be immune mediated and have been reported in subjects receiving FUZEON include primary immune complex reaction, respiratory distress, glomerulonephritis and Guillain-Barre syndrome.
Other Adverse Events: The events most frequently reported in patients receiving FUZEON plus an optimized background regimen were diarrhea (32%), nausea (23%) and fatigue (20%). These events were seen at a lower incidence in patients taking a FUZEON-based regimen compared to those receiving an optimized background regimen without FUZEON when taking into account the uneven number of patients in each arm and the length of time they are in that arm. As measured in number per 100 patient-years, the incidence was: diarrhea (38 per 100 patient-years in subjects receiving FUZEON-based regimens vs. 73 per 100 patient-years in patients who did not receive FUZEON), nausea (27 vs. 50, respectively) and fatigue (24 vs. 38, respectively).
Roche in HIV
Roche is at the forefront of efforts to combat HIV infection and AIDS, committed for 15 years to groundbreaking research and development of new drugs and diagnostic technology. The objective is to provide tailored treatment solutions and an improved standard of care worldwide for people living with HIV.
About Roche - More Than a Century in the U.S. and the World
Founded in 1896 and headquartered in Basel, Switzerland, Roche is one of the world's leading innovation-driven healthcare groups. Its core businesses are pharmaceuticals and diagnostics. Roche is one of the world's leaders in diagnostics, the leading supplier of pharmaceuticals for cancer, as well as a leader in virology and transplantation. As a supplier of products and services for the prevention, diagnosis and treatment of disease, the Group contributes on many fronts to improve people's health and quality of life. Roche employs roughly 65,000 people in 150 countries, including approximately 15,000 in the United States.
Roche's U.S. operations celebrate their American Centennial in 2005. In another milestone this year, Roche was named in January to Fortune magazine's list of Best Companies to Work for in America. One of an increasingly rare breed of major healthcare companies that still bear their original name, Roche today has more than a dozen U.S. sites located in California, Colorado, Indiana, New Jersey and South Carolina, as well as in Puerto Rico. Roche has alliances and research and development agreements with numerous partners, including majority ownership interests in Genentech and Chugai. Roche's Pharmaceuticals Division offers a portfolio of leading medicines in therapeutic areas including cancer, HIV/AIDS, hepatitis C, transplantation, dermatology and influenza. Roche's Diagnostics Division supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our worldwide and U.S. websites (Global: www.roche.com and U.S.: www.roche.us).
For more information on the Roche pharmaceuticals business in the United States, visit the company's web site at www.rocheusa.com.
About Trimeris, Inc.
Trimeris, Inc. (Nasdaq: TRMS) is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. FUZEON, approved in the U.S., Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors. Trimeris is developing FUZEON and future generations of peptide fusion inhibitors in collaboration with F. Hoffmann-La Roche Ltd. For more information about Trimeris, please visit the Company's website at www.trimeris.com.
NUTLEY, N.J. and MORRISVILLE, N.C. – January 27, 2005 – Data recently presented at HIV DART - Frontiers in Drug Development for Antiretroviral Therapies show that patients who were administered a single FUZEON® (enfuvirtide) dose with a needle-free injection device (Biojector® 2000) achieved equivalent drug levels in the blood compared to those who were administered FUZEON with the standard needle (27G ½") and syringe.
This study was a controlled, randomized open-label crossover pharmacokinetic evaluation of HIV-infected patients with viral loads below 1000 copies/mL. The study enrolled 27 patients who received FUZEON for the first time. A study nurse administered single abdominal subcutaneous doses of FUZEON (90mg) with either the Biojector needle-free injection device or a standard 27G ½" needle and syringe. This was followed by a second dose of equal strength administered using the alternate device by the same study nurse, seven days later. The drug levels in the blood were measured over 48 hours and each of the standard comparisons (maximum concentration, minimum concentration, and overall exposure) demonstrated bioequivalence.
The Biojector 2000 injection system, manufactured by Bioject Medical Technologies Inc., is a needle-free CO2-powered injector that disperses fluid through the skin. Biojector 2000 received approval in 1996 to deliver subcutaneous and intramuscular injections and has been used in vaccine delivery, chronic therapy and other settings, delivering millions of injections worldwide (for more information: www.bioject.com or 800.683.7221).
Based on the data from this study, Roche and Trimeris are exploring plans to further evaluate use of FUZEON with this needle-free injection system.
Facts About Fuzeon
FUZEON is the first and only fusion inhibitor for the treatment of HIV. Unlike other HIV drugs that work after HIV has entered the human immune cell, FUZEON works outside the CD4 cell, blocking HIV from entering the cell. For this reason, FUZEON is effective in treatment-experienced patients who have developed resistance to other anti-HIV drugs, though patients may still develop resistance to FUZEON. FUZEON was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in March 2003 on the basis of 24-week data, and was granted traditional (full) approval on Oct. 15, 2004 on the basis of long-term 48-week data.
Injection Site Reactions (ISRs): ISRs are the most common adverse events associated with FUZEON. ISRs occurred in 98% of patients studied and 4% discontinued FUZEON due to ISRs. Signs/symptoms may include pain and discomfort, hardened skin, redness, bumps, itching and swelling. Eleven percent of patients had local reactions that required analgesics or limited usual activities.
Pneumonia: An increased rate of bacterial pneumonia was observed in subjects treated with FUZEON in the Phase III clinical trials compared to the control arm. It is unclear if the increased incidence of pneumonia is related to FUZEON use. Patients with HIV infection should be carefully monitored for signs and symptoms of pneumonia. Risk factors for pneumonia included low initial CD4 cell count, high initial viral load, intravenous drug use, smoking and a prior history of lung disease.
Hypersensitivity Reactions: Systemic hypersensitivity reactions have been associated with FUZEON therapy and may recur on rechallenge. Hypersensitivity reactions have included individually and in combination: rash, fever, nausea and vomiting, chills, rigors, hypotension and elevated serum liver transaminases. Other adverse events that may be immune mediated and have been reported in subjects receiving FUZEON include primary immune complex reaction, respiratory distress, glomerulonephritis and Guillain-Barre syndrome.
Other Adverse Events: The events most frequently reported in patients receiving FUZEON plus an optimized background regimen were diarrhea (32%), nausea (23%) and fatigue (20%). These events were seen at a lower incidence in patients taking a FUZEON-based regimen compared to those receiving an optimized background regimen without FUZEON when taking into account the uneven number of patients in each arm and the length of time they are in that arm. As measured in number per 100 patient-years, the incidence was: diarrhea (38 per 100 patient-years in subjects receiving FUZEON-based regimens vs. 73 per 100 patient-years in patients who did not receive FUZEON), nausea (27 vs. 50, respectively) and fatigue (24 vs. 38, respectively).
Roche in HIV
Roche is at the forefront of efforts to combat HIV infection and AIDS, committed for 15 years to groundbreaking research and development of new drugs and diagnostic technology. The objective is to provide tailored treatment solutions and an improved standard of care worldwide for people living with HIV.
About Roche - More Than a Century in the U.S. and the World
Founded in 1896 and headquartered in Basel, Switzerland, Roche is one of the world's leading innovation-driven healthcare groups. Its core businesses are pharmaceuticals and diagnostics. Roche is one of the world's leaders in diagnostics, the leading supplier of pharmaceuticals for cancer, as well as a leader in virology and transplantation. As a supplier of products and services for the prevention, diagnosis and treatment of disease, the Group contributes on many fronts to improve people's health and quality of life. Roche employs roughly 65,000 people in 150 countries, including approximately 15,000 in the United States.
Roche's U.S. operations celebrate their American Centennial in 2005. In another milestone this year, Roche was named in January to Fortune magazine's list of Best Companies to Work for in America. One of an increasingly rare breed of major healthcare companies that still bear their original name, Roche today has more than a dozen U.S. sites located in California, Colorado, Indiana, New Jersey and South Carolina, as well as in Puerto Rico. Roche has alliances and research and development agreements with numerous partners, including majority ownership interests in Genentech and Chugai. Roche's Pharmaceuticals Division offers a portfolio of leading medicines in therapeutic areas including cancer, HIV/AIDS, hepatitis C, transplantation, dermatology and influenza. Roche's Diagnostics Division supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our worldwide and U.S. websites (Global: www.roche.com and U.S.: www.roche.us).
For more information on the Roche pharmaceuticals business in the United States, visit the company's web site at www.rocheusa.com.
About Trimeris, Inc.
Trimeris, Inc. (Nasdaq: TRMS) is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. FUZEON, approved in the U.S., Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors. Trimeris is developing FUZEON and future generations of peptide fusion inhibitors in collaboration with F. Hoffmann-La Roche Ltd. For more information about Trimeris, please visit the Company's website at www.trimeris.com.
Hat jemand mehr Infos dazu? Habe nur folgendes finden koennen:
Bioject to Report Second Quarter 2011 Financial Results
PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc., (OTCBB: BJCT), a leading developer of needle-free injection therapy systems, announced today that the Company will report its financial results for the second quarter ended June 30, 2011, on Wednesday, August 10, 2011, after the close of the financial markets.
--
Needle Free Injection Technology hoert sich ja nett an. Abwarten.
Bioject to Report Second Quarter 2011 Financial Results
PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc., (OTCBB: BJCT), a leading developer of needle-free injection therapy systems, announced today that the Company will report its financial results for the second quarter ended June 30, 2011, on Wednesday, August 10, 2011, after the close of the financial markets.
--
Needle Free Injection Technology hoert sich ja nett an. Abwarten.
Kann man irgendwo eine Vorabinfo zu den Q2 Zahlen finden? Habe schon gegoogelt aber nur Q1 gefunden.
"Revenue for Q1 2011 improved significantly (+47%) over the prior year ago time period"
Auf der Seite von Bioject.com findet man leider auch nur den Hinweis auf die Pressekonferenz am 10.08.11.
"Revenue for Q1 2011 improved significantly (+47%) over the prior year ago time period"
Auf der Seite von Bioject.com findet man leider auch nur den Hinweis auf die Pressekonferenz am 10.08.11.
Zahlen gibt es wohl am Mittwoch oder Donnerstag.
107% plus im 2nd Quarter. Das kann so weitergehen. Bioject schreibt erstmal schwarze Zahlen.
Second quarter 2011 revenue increased 107% over the same prior year.
www.businesswire.com/news/home/...arter-2011-Financial-Results
Second quarter 2011 revenue increased 107% over the same prior year.
www.businesswire.com/news/home/...arter-2011-Financial-Results
Gabs fuer 7-8 Cents zu kaufen, und wurden heute fuer 0,22-0,25 Cents verkauft. Besser gehts nicht.
War gerade auf der Seite von Bioject.
Hier der Grund warum es so nach oben geht. Es gibt in den USA Grippeimpfung die mit Bioject gemacht wird. Das sind doch gute News.
www.businesswire.com/news/home/...lix-Flu-Season-Immunizations
Bioject®ZetaJet™ to be Utilized by Publix for Flu Season Immunizations
52 stores in the Southeast to begin providing needle-free immunizations in September
PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (OTCBB:BJCT), a leading developer of needle-free injection therapy systems, announced today that beginning in September 2011, select Publix Super Markets (Publix) in the Southeast region will be offering flu season immunizations utilizing the Bioject®ZetaJet™. Publix will be conducting evaluations in 52 stores in Florida, Georgia, Alabama and South Carolina.
“We are pleased that Publix has chosen to offer the Bioject®ZetaJet™ spring-powered device, Bioject’s latest advance in needle-free delivery, for this year’s flu immunizations”
.“We are pleased that Publix has chosen to offer the Bioject®ZetaJet™ spring-powered device, Bioject’s latest advance in needle-free delivery, for this year’s flu immunizations,” said Dr. Richard Stout, Executive Vice President and Chief Medical Officer of Bioject. “The ergonomically- designed Bioject®ZetaJet™ provides patients a convenient alternative to the needle and syringe for the administration of the flu vaccine,” added Dr. Stout.
The Bioject®ZetaJet™, Bioject’s latest advance in needle-free delivery systems, consists of two components, the portable injector and an auto-disabling disposable syringe. It is intended to deliver vaccines and injectable medications up to 0.5 mL either subcutaneously or intramuscularly. The syringe assembly has a unique “auto-disable” feature that prevents its re-use
Hier der Grund warum es so nach oben geht. Es gibt in den USA Grippeimpfung die mit Bioject gemacht wird. Das sind doch gute News.
www.businesswire.com/news/home/...lix-Flu-Season-Immunizations
Bioject®ZetaJet™ to be Utilized by Publix for Flu Season Immunizations
52 stores in the Southeast to begin providing needle-free immunizations in September
PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (OTCBB:BJCT), a leading developer of needle-free injection therapy systems, announced today that beginning in September 2011, select Publix Super Markets (Publix) in the Southeast region will be offering flu season immunizations utilizing the Bioject®ZetaJet™. Publix will be conducting evaluations in 52 stores in Florida, Georgia, Alabama and South Carolina.
“We are pleased that Publix has chosen to offer the Bioject®ZetaJet™ spring-powered device, Bioject’s latest advance in needle-free delivery, for this year’s flu immunizations”
.“We are pleased that Publix has chosen to offer the Bioject®ZetaJet™ spring-powered device, Bioject’s latest advance in needle-free delivery, for this year’s flu immunizations,” said Dr. Richard Stout, Executive Vice President and Chief Medical Officer of Bioject. “The ergonomically- designed Bioject®ZetaJet™ provides patients a convenient alternative to the needle and syringe for the administration of the flu vaccine,” added Dr. Stout.
The Bioject®ZetaJet™, Bioject’s latest advance in needle-free delivery systems, consists of two components, the portable injector and an auto-disabling disposable syringe. It is intended to deliver vaccines and injectable medications up to 0.5 mL either subcutaneously or intramuscularly. The syringe assembly has a unique “auto-disable” feature that prevents its re-use
schaut euch mal paketeria an, da gehts auch um die nadelfreie spritze !
sind vor einigen wochen aus der insolvenz gekommen und haben schon gute verträge an der hand.
gruß stockworld
sind vor einigen wochen aus der insolvenz gekommen und haben schon gute verträge an der hand.
gruß stockworld
Das haettest du mal vor 1-2 Wochen posten sollen:
Die Experten vom "Geldanlage-Report" raten bei der Aktie von Paketeria (ISIN DE000A0STYL7/ WKN A0STYL) zunächst außen vor zu bleiben und Zockern auf einen deutlichen Rücksetzer zu warten. Mit plus 113 Prozent habe Paketeria innerhalb einer Woche prozentual dreistellig zugelegt.
--
Wenn es beim Nasdaq fuer Bioject heute nach oben geht, verkaufe ich meinen Rest. 0,40 Cents waere ok.
Die Experten vom "Geldanlage-Report" raten bei der Aktie von Paketeria (ISIN DE000A0STYL7/ WKN A0STYL) zunächst außen vor zu bleiben und Zockern auf einen deutlichen Rücksetzer zu warten. Mit plus 113 Prozent habe Paketeria innerhalb einer Woche prozentual dreistellig zugelegt.
--
Wenn es beim Nasdaq fuer Bioject heute nach oben geht, verkaufe ich meinen Rest. 0,40 Cents waere ok.
Endlich kann man sich mal auf die Grippe Saison freuen :-)
Warum weichen die beiden Kurse immer 10 Cents voneinander ab?
Waere fuer Bioject sicherlich gut, wenn bald die Grippewelle losgeht..
Gibt es diese nadelosen Spritzen eigentlich in Deutschland?
Gibt es diese nadelosen Spritzen eigentlich in Deutschland?
Times & Sales Zeit Kurs Stück
18:14:55 0,089 20000.0
18:14:08 0,090 247500.0
18:06:16 0,080 37500.0
18:04:58 0,080 100000.0
18:03:40 0,12 70000.0
18:00:31 0,12 25000.0
17:47:33 0,15 20000.0
09:05:08 0,0010 0.0
---
Auf deren Seite habe ich nichts neues gefunden, nur das die einen neuen CEO haben.
18:14:55 0,089 20000.0
18:14:08 0,090 247500.0
18:06:16 0,080 37500.0
18:04:58 0,080 100000.0
18:03:40 0,12 70000.0
18:00:31 0,12 25000.0
17:47:33 0,15 20000.0
09:05:08 0,0010 0.0
---
Auf deren Seite habe ich nichts neues gefunden, nur das die einen neuen CEO haben.
Das letzte Quartal war wohl bombig, nachdem lange Verlust gemacht wurde, gab es endlich mal wieder Gewinn. Danach gabs dann Probleme mit einer Zulassung, und es wird ueber den evtl. Verkauf spekuliert. Steht zumind. auf deren Seite. Vielleicht gibt es ja einen Kaeufer. 8800% plus (ohne Leerverkaeufe) sieht man nicht alle Tage.
Leider kommt man nie fuer 1-2-3 Cents rein.
Times & Sales
Zeit Kurs Stück
11:34:53 0,061 30000.0
09:43:56 0,095 100000.0
09:34:32 0,10 50000.0
09:05:08 0,0050 0.0
Times & Sales
Zeit Kurs Stück
11:34:53 0,061 30000.0
09:43:56 0,095 100000.0
09:34:32 0,10 50000.0
09:05:08 0,0050 0.0
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem BIOJECT MEDICAL TECHS Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 27 | Bioject Medical Technologies!!! | soros | DR.Carre | 06.02.12 13:48 |